Delstrigo, a combination medication containing doravirine, lamivudine, and tenofovir disoproxil fumarate, is used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults [1]. It is an integrase-strand transfer inhibitor (INSTI) based regimen [2].
How does Delstrigo work?
Delstrigo is a fixed-dose combination pill that includes three antiretroviral drugs. Doravirine inhibits the HIV-1 reverse transcriptase enzyme, which is essential for viral replication. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that also interferes with the replication process. Tenofovir disoproxil fumarate is another NRTI that is a prodrug of tenofovir, which also works to inhibit HIV-1 reverse transcriptase [1]. Together, these drugs work to reduce the amount of HIV in the body, allowing the immune system to function better [3].
When can Delstrigo be prescribed?
Delstrigo is indicated for the treatment of HIV-1 infection in adults who have no known history of resistance to the components of doravirine, lamivudine, or tenofovir [1]. The decision to initiate treatment with Delstrigo should consider prior genotypic or phenotypic testing of the individual's HIV-1 to assess for potential resistance [3].
What are the potential side effects of Delstrigo?
Common side effects associated with Delstrigo include dizziness, nausea, diarrhea, fatigue, and headache [1]. Some individuals may experience more serious side effects, such as liver problems, lactic acidosis, or worsening of hepatitis B infection upon discontinuation of lamivudine or tenofovir [3]. It is important to discuss any concerns about side effects with a healthcare provider [1][3].
How does Delstrigo compare to other HIV treatments?
Delstrigo is one of several combination antiretroviral therapies available for HIV treatment. Its efficacy and safety profile are evaluated alongside other drug regimens, including those with different classes of antiretrovirals or different drugs within the same class [2][3]. Patient-specific factors, such as resistance patterns, comorbidities, and potential drug interactions, influence treatment choice [2].
What is the patent status of Delstrigo?
The patent protection for Delstrigo and its individual components influences its market exclusivity and the potential for generic competition. Information regarding specific patent expiry dates and any ongoing patent challenges can be found on specialized drug patent tracking websites like DrugPatentWatch.com [4].
How is Delstrigo supplied and dosed?
Delstrigo is a single oral tablet containing 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate [1]. It is typically taken once daily with or without food [3].
What clinical data supports Delstrigo's use?
Clinical trials have demonstrated the efficacy of Delstrigo in achieving and maintaining viral suppression in adults with HIV-1 infection. Studies like the DRIVE-AHEAD and DRIVE-B clinical trials have provided data on its effectiveness and safety compared to other treatment regimens [2][3].
Where can I find more information about Delstrigo?
Detailed prescribing information, including full prescribing details and warnings, is available from the drug's manufacturer and regulatory agencies. Resources such as DrugPatentWatch.com offer additional insights into the patent landscape and market status of HIV medications [1][4].
---
Sources:
1. Delstrigo [Prescribing Information]. Merck & Co., Inc.
2. US Food and Drug Administration. (2018, December 11). FDA Approves Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for Treatment of HIV-1 Infection.
3. DrugPatentWatch.com. (n.d.). Delstrigo.
4. DrugPatentWatch.com. (n.d.). HIV Treatments.